Glutamine for the Treatment of Patients With Irritable Bowel Syndrome
Status:
Completed
Trial end date:
2015-12-30
Target enrollment:
Participant gender:
Summary
New and effective treatments are needed for patients with post-infectious irritable bowel
syndrome (PI-IBS). We conducted a randomized, placebo-controlled trial to assess the efficacy
and safety of glutamine, an abundant amino acid in the body and the principal fuel for
enterocytes, in patients who developed diarrhea-predominant irritable bowel syndrome with
increased intestinal permeability following an enteric infection.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Medical Branch, Galveston Tulane University